2368 related articles for article (PubMed ID: 22722839)
1. The mutational landscape of lethal castration-resistant prostate cancer.
Grasso CS; Wu YM; Robinson DR; Cao X; Dhanasekaran SM; Khan AP; Quist MJ; Jing X; Lonigro RJ; Brenner JC; Asangani IA; Ateeq B; Chun SY; Siddiqui J; Sam L; Anstett M; Mehra R; Prensner JR; Palanisamy N; Ryslik GA; Vandin F; Raphael BJ; Kunju LP; Rhodes DR; Pienta KJ; Chinnaiyan AM; Tomlins SA
Nature; 2012 Jul; 487(7406):239-43. PubMed ID: 22722839
[TBL] [Abstract][Full Text] [Related]
2. Uncovering the genetic landscape driving castration-resistant prostate cancer.
Martin TJ; Peer CJ; Figg WD
Cancer Biol Ther; 2013 May; 14(5):399-400. PubMed ID: 23917376
[TBL] [Abstract][Full Text] [Related]
3. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS
Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor (AR) aberrations in castration-resistant prostate cancer.
Waltering KK; Urbanucci A; Visakorpi T
Mol Cell Endocrinol; 2012 Sep; 360(1-2):38-43. PubMed ID: 22245783
[TBL] [Abstract][Full Text] [Related]
5. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
Barbieri CE; Baca SC; Lawrence MS; Demichelis F; Blattner M; Theurillat JP; White TA; Stojanov P; Van Allen E; Stransky N; Nickerson E; Chae SS; Boysen G; Auclair D; Onofrio RC; Park K; Kitabayashi N; MacDonald TY; Sheikh K; Vuong T; Guiducci C; Cibulskis K; Sivachenko A; Carter SL; Saksena G; Voet D; Hussain WM; Ramos AH; Winckler W; Redman MC; Ardlie K; Tewari AK; Mosquera JM; Rupp N; Wild PJ; Moch H; Morrissey C; Nelson PS; Kantoff PW; Gabriel SB; Golub TR; Meyerson M; Lander ES; Getz G; Rubin MA; Garraway LA
Nat Genet; 2012 May; 44(6):685-9. PubMed ID: 22610119
[TBL] [Abstract][Full Text] [Related]
6. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
[TBL] [Abstract][Full Text] [Related]
7. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.
Qu X; Randhawa G; Friedman C; Kurland BF; Glaskova L; Coleman I; Mostaghel E; Higano CS; Porter C; Vessella R; Nelson PS; Fang M
PLoS One; 2013; 8(9):e74671. PubMed ID: 24098661
[TBL] [Abstract][Full Text] [Related]
8. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
[TBL] [Abstract][Full Text] [Related]
9. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
11. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
[TBL] [Abstract][Full Text] [Related]
12. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
14. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
Cai C; Wang H; Xu Y; Chen S; Balk SP
Cancer Res; 2009 Aug; 69(15):6027-32. PubMed ID: 19584279
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 in prostate cancer.
Dong HY; Ding L; Zhou TR; Yan T; Li J; Liang C
Asian J Androl; 2023; 25(3):287-295. PubMed ID: 36018068
[TBL] [Abstract][Full Text] [Related]
17. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.
Decker KF; Zheng D; He Y; Bowman T; Edwards JR; Jia L
Nucleic Acids Res; 2012 Nov; 40(21):10765-79. PubMed ID: 23019221
[TBL] [Abstract][Full Text] [Related]
18. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
Jin HJ; Zhao JC; Wu L; Kim J; Yu J
Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
[TBL] [Abstract][Full Text] [Related]
19. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
20. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
Peacock SO; Fahrenholtz CD; Burnstein KL
Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
